Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

ESLA

Estrella Immunopharma Inc

Dec 13 • 04:00PM ET

1.19

Dollar change -0.04
Percentage change -3.34	%

Healthcare • Biotechnology • USA • NASD

Peers: MRNA NVAX BNTX PFE JNJ REGN GILD VRTX AZN LLY

| Held by: IWC VTI VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.24	Insider Own	72.09%	Shs Outstand	35.20M	Perf Week	-1.18%
Market Cap	41.75M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	10.10M	Perf Month	42.11%
Income	-8.82M	PEG	-	EPS next Q	-	Inst Own	0.55%	Short Float	0.37%	Perf Quarter	23.06%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	48.63%	Short Ratio	0.27	Perf Half Y	26.99%
Book/sh	0.02	P/B	56.31	EPS next Y	-	ROA	-56.73%	Short Interest	0.04M	Perf Year	-10.25%
Cash/sh	0.05	P/C	23.19	EPS next 5Y	-	ROE	-163.06%	52W Range	0.63 - 3.23	Perf YTD	7.54%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-1181.58%	52W High	-63.04%	Beta	0.46
Dividend TTM	-	Quick Ratio	0.75	Sales past 5Y	-	Gross Margin	-	52W Low	89.48%	ATR (14)	0.17
Dividend Ex-Date	-	Current Ratio	0.75	EPS Y/Y TTM	-32.79%	Oper. Margin	-	RSI (14)	55.87	Volatility	18.70% 14.47%
Employees	-	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	-	Target Price	-
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	94.75%	Payout	-	Rel Volume	0.03	Prev Close	1.23
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	138.60K	Price	1.19
SMA20	7.49%	SMA50	24.86%	SMA200	8.39%	Trades		Volume	3,577	Change	-3.34%

Sep-27-24 12:00PM	Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS T-cells (Business Wire) +22.69%
Aug-14-24 12:00PM	Estrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board Member (Business Wire)
Aug-02-24 07:34AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace) -18.08%
May-20-24 10:52AM	ESLA Stock Earnings: Estrella Immunopharma Reported Results for Q3 2024 (InvestorPlace)
Sep-29-23 10:34AM	TradeUP Acquisition Corp. and Estrella Biopharma, Inc. Announce Completion of Business Combination (PR Newswire) -6.22%
05:00PM	Loading…
Sep-18-23 05:00PM	TradeUP Acquisition Corp. Announces Extension of the Deadline for an Initial Business Combination (PR Newswire) +34.29% -17.25%
Aug-18-23 04:30PM	TradeUP Acquisition Corp. Announces Extension of the Deadline for an Initial Business Combination (PR Newswire)
Jul-18-23 04:30PM	TradeUP Acquisition Corp. Announces Extension of the Deadline for an Initial Business Combination (PR Newswire)
Jul-12-23 07:00AM	TradeUP Acquisition Corp. Announces Meeting Date for Stockholders to Approve the Business Combination with Estrella Biopharma, Inc. and Liquidation of Investments Held in the Trust Account into Cash (PR Newswire)

Estrella Immunopharma, Inc. operates as a pre-clinical stage biopharmaceutical company, which engages in the development of T-cell therapies for patients with cancers and autoimmune diseases. The company was founded on March 30, 2022 and is headquartered in Emeryville, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ESLA

Estrella Immunopharma Inc

Upgrade your FINVIZ experience